That sentiment is at the heart of this week’s selloff: while Gelsinger’s turnaround was taking too long, it may have been ...
Pat Gelsinger’s reign at Intel began nearly four years ago with a flood of initiatives and hope for the future of the tech ...
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate ...